GlassScriptPhysician profile
Marisa Adlesich
NPI 1679047708
$1,620.51
in general payments reported to CMS, 2019-2025
35 companies · $621 in 2025
The $621 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $127 · 2023: $251 · 2024: $621 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $147.22 | 2023-2025 | Phesgo, Kadcyla, Polivy |
| Pfizer INC. | $146.19 | 2022-2025 | |
| Abbvie INC. | $129.95 | 2024 | |
| Daiichi Sankyo INC. | $114.61 | 2022-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $104.51 | 2025 | |
| Genzyme Corporation | $100.74 | 2024-2025 | |
| Astellas Pharma US INC | $73.57 | 2024-2025 | Padcev, Xospata, Vyloy |
| Glaxosmithkline, LLC. | $72.58 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Sobi, INC | $69.64 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $49.91 | 2024-2025 | Orgovyx |
| Gilead Sciences, INC. | $45.61 | 2022-2024 | |
| Tersera Therapeutics LLC | $32.06 | 2025 | Zoladex |
| Amgen INC. | $31.83 | 2023 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $31.79 | 2025 | |
| Organon LLC | $28.70 | 2023 | Ontruzant |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $26.81 | 2025 | |
| Genmab U.S., INC. | $26.09 | 2025 | Epkinly |
| Tempus Ai, INC | $26.02 | 2024 | Xt Cdx |
| Lilly USA, LLC | $25.60 | 2025 | Jaypirca, Verzenio |
| Mirati Therapeutics, INC. | $24.91 | 2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $24.48 | 2024 | Opdualag |
| Kite Pharma, INC. | $23.76 | 2025 | Yescarta |
| Beigene USA, INC. | $23.64 | 2023 | Brukinsa |
| Blueprint Medicines Corporation | $23.20 | 2022 | |
| Morphosys, US INC. | $22.32 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $22.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.18 | 2024 | Iclusig |
| Astrazeneca Pharmaceuticals LP | $20.78 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.01 | 2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $19.69 | 2022 | |
| Caris Mpi, INC. | $19.66 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $19.11 | 2025 | Keytruda |
| Emd Serono, INC. | $18.65 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.56 | 2025 | Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Adlesich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.